Crystal Adam sold $736K of TNGX
Crystal Adam (President, R&D) sold 27,000 shares of Tango Therapeutics, Inc. (TNGX) at an average of $27.24 ($26.79–$27.35, $0.74M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Crystal Adam, President of R&D, executed open-market sales totaling about $735.5K across two trades on 2026-08-03, with holdings after the transaction of 115,743 shares.
Market read
Traders may note the insider sale as a sentiment datapoint, but the 10b5-1 structure suggests limited incremental fundamental information.
What to watch
Insider sales can be misread without context on total insider holdings, other concurrent transactions, and whether the plan size is routine versus unusual.
Background
The article is a SEC Form 4 insider transaction disclosure for Tango Therapeutics, Inc.
Ticker impact
Tango Therapeutics insider Crystal Adam sold about 27,000 shares for roughly $735.5K under a pre-arranged 10b5-1 plan.
Low likelihood of sustained price impact; any reaction is likely short-lived unless paired with other new company catalysts.
The filing is a Form 4 insider transaction with a stated 10b5-1 plan, which typically reduces the signal of immediate negative information.
Market effects
No clear sector read-through from a single 10b5-1 insider sale at one biotech.
None indicated.
None indicated.
Counterpoint
The sale could reflect diversification or liquidity needs rather than bearish expectations, especially given the pre-arranged 10b5-1 plan.
Key entities
- issuerTango Therapeutics, Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderCrystal Adam
President, R&D, who sold shares under a pre-arranged 10b5-1 plan.